Imperial College London

DrManikandanPeriyasamy

Faculty of MedicineDepartment of Surgery & Cancer

Laboratory Projects Manager
 
 
 
//

Contact

 

+44 (0)20 7594 2818m.periyasamy Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Summary


Selected Publications

Journal Articles

Ali S, Patel H, Periyasamy M, et al., 2018, ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment, Molecular Cancer Therapeutics, ISSN:1535-7163

Harrod A, Fulton J, Nguyen VTM, et al., 2016, Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer, Oncogene, Vol:36, ISSN:1476-5594, Pages:2286-2296

Patel H, Abduljabbar R, Lai CF, et al., 2016, CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer, Clinical Cancer Research, Vol:22, ISSN:1557-3265, Pages:5929-5938

Mollet IG, Patel D, Govani FS, et al., 2016, Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes, PLOS One, Vol:11, ISSN:1932-6203

Nguyen VTM, Barozzi I, Faronato M, et al., 2015, Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion, Nature Communications, Vol:6, ISSN:2041-1723

Ali S, Periyasamy M, Patel H, et al., 2015, APOBEC3B mediated cytidine deamination is required for estrogen receptor action in breast cancer, Cell Reports, Vol:13, ISSN:2211-1247, Pages:108-121

Kramer H, Lai C, Dattani H, et al., 2015, LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner, Nucleic Acids Research, Vol:44, ISSN:1362-4962, Pages:582-594

Lin M-L, Patel H, Remenyi J, et al., 2015, Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer, Oncotarget, Vol:6, ISSN:1949-2553, Pages:21685-21703

Stebbing J, Zhang H, Xu Y, et al., 2015, KSR1 regulates BRCA1 degradation and inhibits breast cancer growth, Oncogene, Vol:34, ISSN:0950-9232, Pages:2103-2114

Pellegrino L, Stebbing J, Braga VM, et al., 2013, miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts, Nucleic Acids Research, Vol:41, ISSN:1362-4962, Pages:5400-5412

Zhang H, Lombardo Y, Filipovic A, et al., 2012, KSR1 is involved in functional interaction between p53 and BRCA1 and is an independent predictor of overall survival in breast cancer, Cancer Research, Vol:72, ISSN:0008-5472

Lombardo Y, Filipovic A, Molyneux G, et al., 2012, Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo, Proceedings of the National Academy of Sciences of the United States of America, Vol:109, ISSN:0027-8424, Pages:16558-16563

Tolhurst RS, Thomas RS, Kyle FJ, et al., 2011, Transient over-expression of estrogen receptor-alpha in breast cancer cells promotes cell survival and estrogen-independent growth, Breast Cancer Research and Treatment, Vol:128, ISSN:0167-6806, Pages:357-368

Thiruchelvam PTR, Lai C-F, Hua H, et al., 2011, The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells, Breast Cancer Research and Treatment, Vol:127, ISSN:0167-6806, Pages:385-396

Heathcote DA, Patel H, Kroll SH, et al., A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration, J Med Chem, Vol:53, Pages:8508-8522

WORTHAM NC, AHAMED E, NICHOL SM, et al., 2009, The DEAD-box protein p72 regulates ERα-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERα-positive breast cancer, Oncogene, Vol:28, ISSN:1476-5594, Pages:4053-4064

Ali S, Heathcote DA, Kroll SHB, et al., 2009, The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity, Cancer Research, Vol:69, ISSN:0008-5472, Pages:6208-6215

Coombes R, Cheiper, Jogalekar AS, et al., 2009, The development of a selective CDK7 inhibitor with anti-tumor activity, Cancer Research, Vol:69, ISSN:0008-5472

Periyasamy M, Thomas R, Tolhurst R, et al., 2009, Investigation of the regulation of DNA methylation by the estrogen receptor, Cancer Research, Vol:69, ISSN:0008-5472

Lopez-Garcia J, Periyasamy M, Thomas RS, et al., 2006, ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases, Nucleic Acids Research, Vol:34, ISSN:1362-4962, Pages:6126-6136

Conference

Fulton J, Harrod A, Van N, et al., 2016, Use of CRISPR-Cas9-mediated knockin mutagenesis of ESR1 mutations in metastatic breast cancer allow functional analysis and evaluation of treatment options, UK Breast Cancer Research Symposium, SPRINGER, Pages:193-193, ISSN:0167-6806

Ali S, Patel H, Periyasamy M, et al., 2016, ICEC0942, an orally bioavailable selective inhibitor of CDK7 for breast cancer, UK Breast Cancer Research Symposium, Springer Verlag, Pages:195-195, ISSN:0167-6806

More Publications